Biologically active proteins having increased in vivo and/or in vitro stability
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-001/00
A61K-038/24
C07K-014/00
C07K-014/56
C07K-007/06
C07K-007/08
C07K-014/415
C12N-015/10
G01N-033/68
C07K-014/47
C07K-014/53
C07K-014/61
C07K-014/535
A61K-038/00
출원번호
US-0970723
(2015-12-16)
등록번호
US-9938331
(2018-04-10)
발명자
/ 주소
Schellenberger, Volker
Stemmer, Willem P.
Wang, Chia-Wei
Scholle, Michael D.
Gordon, Nathaniel C.
Crameri, Andreas
Popkov, Mikhail
출원인 / 주소
Amunix Operating Inc.
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
1인용 특허 :
129
초록▼
The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention al
The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
대표청구항▼
1. An unstructured recombinant polymer (URPs), wherein the URP comprising at least about 200 contiguous amino acids, and wherein (a) the sum of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues contained in the URP, constitutes more than about
1. An unstructured recombinant polymer (URPs), wherein the URP comprising at least about 200 contiguous amino acids, and wherein (a) the sum of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues contained in the URP, constitutes more than about 80% of the total amino acids of the URP;(b) at least 50% of the amino acids of the URP are not present in secondary structure as determined by Chou-Fasman algorithm;(c) the URP has a Tepitope score equal to or less than −5;(d) the URP contains only 3, 4, 5, or 6 different types of amino acids; and(e) the URP contains greater than 5% glutamic acid and less than 2% lysine or arginine;wherein incorporation of the URP into a heterologous protein results in a fusion protein having at least a 2-fold increase in apparent molecular weight of the fusion protein as compared to the protein lacking said URP wherein the apparent molecular weight is approximated by size exclusion chromatography, and wherein the fusion protein exhibits an increased half-life as compared to the protein lacking said URP. 2. The URP of claim 1, wherein upon incorporation of the URP into an N-terminus, a C-terminus, into a loop of the heterologous protein, or between domains of the heterologous protein to create a monomeric fusion protein, said heterologous protein exhibits a serum secretion half-life that is at least two-fold longer as compared to the corresponding protein that is deficient in said URP. 3. The URP of claim 1, wherein the URP comprises a non-natural amino acid sequence. 4. The URP of claim 1, wherein the URP comprises at least 400 contiguous amino acids. 5. The URP of claim 1, wherein the URP comprises at least five types of amino acids selected from the group consisting of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P). 6. The URP of claim 1, wherein the URP comprises at least six types of amino acids selected from the group consisting of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P). 7. The URP of claim 1, wherein one type of the amino acids selected from the group consisting of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) constitutes at least 20% of the total amino acids of the URP. 8. The URP of claim 7, wherein the one type of amino acid is glutamate (E). 9. The URP of claim 1, wherein any one type of amino acid is no more than 30% of the total amino acids of the URP. 10. The URP of claim 1, wherein the heterologous protein is a pharmaceutically active protein. 11. The URP of claim 1, wherein the heterologous protein comprises one or more modules selected from the group consisting of binding modules, effector modules, multimerization modules, C-terminal modules, and N-terminal modules. 12. The URP of claim 10, wherein the pharmaceutically active protein is selected from the group consisting of cytokines, growth factors, enzymes, receptors, microproteins, hormones, erythopoetin, adenosine deiminase, asparaginase, arginase, interferon, growth hormone, growth hormone releasing hormone, G-CSF, GM-CSM, insulin, hirudin, TNF-receptor, uricase, rasburicase, axokine, RNAse, DNAse, phosphatase, pseudomonas exotoxin, ricin, gelonin, desmoteplase, laronidase, thrombin, blood clotting enzyme, VEGF, protropin, somatropin, alteplase, interleukin, factor VII, factor VIII, factor X, factor IX, dornase, glucocerebrosidase, follitropin, glucagon, thyrotropin, nesiritide, alteplase, teriparatide, agalsidase, laronidase, methioninase. 13. The URP of claim 1, wherein any amino acids of the URP that are not glycine, aspartate, alanine, serine, threonine, glutamate, or proline are not hydrophobic amino acids selected from the group consisting of tryptophan, tyrosine, phenylalanine, methionine, leucine, isoleucine, and valine.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (129)
Knopf, John; Seehra, Jasbir, ActRII receptor polypeptides, methods and compositions.
Curtis Joseph E. (Glendora CA) Helgerson Sam L. (Pasadena CA) Lundblad Roger L. (Chapel Hill NC) Liu Shu-Len (Cerritos CA), Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency.
Silverman, Joshua; Schellenberger, Volker; Stemmer, Willem P.; Wang, Chia-Wei; Brennan, Ian M., Alpha 1-antitrypsin compositions and methods of making and using same.
Schellenberger, Volker; Silverman, Joshua; Wang, Chia-wei; Spink, Benjamin; Stemmer, Willem P.; Geething, Nathan, Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same.
Lillicrap David,CAX ; Cameron Cherie,CAX ; Notley Colleen,CAX ; Hoyle Horrocks L. Suzanne,CAX ; Hough Christine,CAX, Canine factor VIII gene, protein and methods of use.
Schellenberger, Volker; Silverman, Joshua; Stemmer, Willem; Wang, Chia-wei; Spink, Benjamin; Geething, Nathan; To, Wayne, Coagulation factor VII compositions and methods of making and using same.
Osterberg Thomas,SEX ; Fatouros Angelica,SEX, Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabi.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Composition for delivering bioactive agents for immune response and its preparation.
Qiu, Yihong; Bollinger, J. Daniel; Cheskin, Howard S.; Dutta, Sandeep; Engh, Kevin R.; Poska, Richard P., Controlled release formulation of divalproex sodium.
Prausnitz, Mark R.; Allen, Mark G.; Henry, Sebastien; McAllister, Devin V.; Ackley, Donald E.; Jackson, Thomas, Devices and methods for enhanced microneedle penetration of biological barriers.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Lenting, Petrus Johannes; Van Mourik, Jan Aart; Mertens, Koenraad; Pannekoek, Hans; Turecek, Peter; Schwarz, Hans-Peter; Scheiflinger, Friedrich, Factor VII polypeptide having factor VII:C activity.
Meulien Pierre (Strasbourg FRX) Pavirani Andrea (Strasbourg FRX), Factor VIII analog, preparation process, and pharmaceutical composition containing it.
Schellenberger, Volker; Silverman, Joshua; Stemmer, Willem P.; Wang, Chia-wei; Geething, Nathan; Cleland, Jeffrey L., Glucose-regulating polypeptides and methods of making and using same.
Schellenberger, Volker; Silverman, Joshua; Stemmer, Willem P.; Wang, Chia-wei; Geething, Nathan; Cleland, Jeffrey L.; Spink, Benjamin, Growth hormone polypeptides and methods of making and using same.
Schellenberger, Volker; Silverman, Joshua; Wang, Chia-wei; Stemmer, Willem P.; Geething, Nathan; Cleland, Jeffrey L., Growth hormone polypeptides and methods of making and using same.
Schellenberger, Volker; Silverman, Joshua; Stemmer, Willem P.; Wang, Chia-Wei; Geething, Nathan; Cleland, Jeffrey L., Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same.
Cunningham Brian C. (Piedmont CA) Lowman Henry (Hercules CA) Wells James A. (Burlingame CA), Human growth hormone variants having greater affinity for human growth hormone receptor at site 1.
Tice, Thomas R.; Lewis, Danny H.; Cowsar, Donald R.; Beck, Lee R., Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents.
Turner Terry L. (Charlottesville VA) Howards Stuart S. (Charlottesville VA), Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Kuo George (San Francisco CA) Masiarz Frank (San Francisco CA) Truett Martha (Oakland CA) Valenzuela Pablo (San Francisco CA), Method and composition for preparation of factor VIIIC.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their.
D\Arrigo Joseph S. (Farmington CT), Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and the.
Spira Jack,SEX ; Widlund Lars,SEX ; Osterberg Thomas,SEX, Method for treatment of hemophilia by extravascular administration of factor VIII deletion derivatives.
Jolly, Douglas J.; Chang, Stephen; Respess, James G.; DePolo, Nicholas J.; Hsu, David Chi-Tang; Ibanez, Carlos E.; Greengard, Judith; Will, Lee, Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders.
Schellenberger, Volker; Stemmer, Willem P.; Wang, Chia-wei; Scholle, Michael D.; Popkov, Mikhail; Gordon, Nathaniel C.; Crameri, Andreas, Methods for production of unstructured recombinant polymers and uses thereof.
Andrew S. Janoff ; Thomas D. Madden CA; Pieter R. Cullis CA; John J. Kearns ; Anthony G. Durning, Methods of preparing low-toxicity drug-lipid complexes.
Tice, Thomas R.; Dillon, Deborah L.; Mason, David W.; McRae-McFarlane, Amanda; Dahlstrom, Annica B., Microcapsules for administration of neuroactive agents.
Harrison Juan M. E. (Mountain View CA) Barclay Brian L. (Sunnyvale CA) Childers Jerry D. (Menlo Park CA) Wright Jeri D. (Dublin CA) Place Virgil A. (Kawaihae HI) Wong Patrick S. (Palo Alto CA), Oral osmotic device with hydrogel driving member.
Popescu Mircea C. ; Weiner Alan L. ; Recine Marie S. ; Janoff Andrew S. ; Estis Leonard ; Keyes Lynn D. ; Alving Carl R., Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use.
Capon Daniel J. (San Mateo CA) Lawn Richard M. (San Francisco CA) Levinson Arthur D. (Hillsborough CA) Vehar Gordon A. (San Carlos CA) Wood William I. (San Mateo CA), Preparation of functional human factor VIII in mammalian cells using methotrexate based selection.
Chapman Barbara ; Burke Rae Lyn ; Rasmussen Mirella Ezban,DKX ; Mikkelson Jan Moller,DKX, Protein complexes having Factor VIII:C activity and production thereof.
Van Ooyen Albert Johannes Joseph,NLX ; Pannekoek Hans,NLX ; Verbeet Martinus Philippus,NLX ; Van Leen Robert Willem,NLX, Proteins with Factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them.
van Ooyen Albert J. J. (Voorburg NLX) Pannekoek Hans (Aalsmeer NLX) Verbeet Martinus P. (Amsterdam NLX) van Leen Robert W. (Nijmegen NLX), Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical.
Albert Johannes Joseph Van Ooyen NL; Hans Pannekoek NL; Martinus Philippus Verbeet NL; Robert Willem Van Leen NL, Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them.
Edward M. Rudnic ; Beth A. Burnside ; Henry H. Flanner ; Sandra E. Wassink ; Richard A. Couch ; Jill E. Pinkett, Soluble form osmotic dose delivery system.
Rudnic Edward M. ; Burnside Beth A. ; Flanner Henry H. ; Wassink Sandra E. ; Couch Richard A. ; Pinkett Jill E., Soluble form osmotic dose delivery system.
Rudnic, Edward M.; Burnside, Beth A.; Flanner, Henry H.; Wassink, Sandra E.; Couch, Richard A.; Pinkett, Jill E., Soluble form osmotic dose delivery system.
D\Arrigo Joseph S. (23A Brickyard Rd. Farmington CT 06032), Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures.
Wheatley Margaret A. (Norristown PA) Langer Robert S. (Somerville MA) Eisen Herman N. (Waban MA), System for controlled release of biologically active compounds.
Adler-Moore Jill ; Gamble Ronald C. ; Proffitt Richard T., Treatment of systemic fungal infections with phospholipid particles encapsulating polyene antibiotics.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.